Interleukin-2 Deficit in Hemodialysis Patients. Role of Prostaglandins

References

• Dammin G J, Couch N P, Murray JE. Prolonged survival of skin homografts in uremic patients. Ann NY Acad Sci 1957; 64: 967–976
   PubMedGoogle Scholar
• Matas A J, Simmons R L, Kjellstrand C M, Buselmeier T J, Najarian JS. Increased incidence of malignancy in chronic renal failure. Lancet 1975; 1: 883–885
   PubMed Web of Science ®Google Scholar
• Lindner A, Farewell V T, Sherrard DJ. High incidence of neoplasias in uremic patients receiving long term dialysis. Nephron 1981; 27: 292–296
   PubMed Web of Science ®Google Scholar
• Kirkpatrick C H, Wilson W EC, Talmage DW. Observation and characterization of suppressed cutaneous reactivity in uremia. J Exp Med 1964; 119: 727–742
   PubMed Web of Science ®Google Scholar
• Lopez M, Jerez J, Gonzalez M, Arias M. Cell-mediated immunity in healthy and uremic adults assessed by in vivo and in vitro techniques. Validation of delayed hypersensitivity skin testing. Allergol et Immunopathol 1989; 17: 21–28
   PubMedGoogle Scholar
• Meuer S C, Hauer M, Kurz P, Meyer Zum B H, ÜSchenfelde K, KÖHler H. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest 1987; 80: 743–749
   PubMed Web of Science ®Google Scholar
• Dobbelstein H. Immune system in uremia. Nephron 1976; 17: 409–414
   PubMed Web of Science ®Google Scholar
• Kunori 1, Fehrman I, Ringden D, Moller E. In vitro characterization of immunological responsiveness of uremic patients. Nephron 1980; 26: 234–239
   PubMed Web of Science ®Google Scholar
• Kurz P, KÖHler H, Meuer S, Hutteroth T, Meyer Zum BÜSchenfelde KH. Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int. 1986; 29: 1209–1214
   PubMedGoogle Scholar
• Holdsworth S R, Fitzgerald M G, Hosking C S, Atkins RC. The effect of maintenance dialysis on lymphocyte function. I. Haemodialysis. Clin Exp Immunol 1978; 33: 95–101
   PubMedGoogle Scholar
• Touraine J L, Touraine F, Revillard J P, Brochier J, Traeger J. T-lymphocytes and serum inhibitors of cell-mediated immunity in renal insufficiency. Nephron 1975; 14: 196–208
   Google Scholar
• Chouaib S, Welte K, Mertelsmann R, Dupont B. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin-2 production and down-regulation of transferrin receptor expression. J Immunol 1985; 135: 1172–1179
   PubMed Web of Science ®Google Scholar
• Chouaib S, Bertoglio JH. Prostaglandins E as modulators of the immune response. Lymphokine Res 1988; 7: 237–245
   PubMedGoogle Scholar
• Chatenoud L, Dugas B, Beaurain Touam G. M., Drueke T, Vasquez A, Galanaud P, Bach J F, Delfraissy JF. Presence of pre-activated T cells in hemodialyzed patients: their possible role in altered immunity. Proc Natl Acad Sci 1986; 83: 7457–7461
   PubMed Web of Science ®Google Scholar
• Langhoff E, Hofmann B, Odum N, Ladefoged J, Platz P, Ryder L P, Svejgaard A. Kinetic analysis of interleukin-2 (IL-2) production and expression of IL-2 receptors by uremic and normal lymphocytes. Scand J. Immunol 1987; 25: 29–36
   PubMedGoogle Scholar
• Tucker S B, Pierre R V, Jordan RE. Rapid identification of monocytes in a mixed mononuclear cell preparation. J Immunol Meth 1977; 14: 267–271
   PubMed Web of Science ®Google Scholar
• Tsakolos N D, Theoharides ThC, Hendler E D, Goffinet J, Dwyer J M, Whisler R L, Askenase PW. Immune defects in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on haemodialysis. Clin Exp Immunol 1986; 63: 218–227
   PubMed Web of Science ®Google Scholar
• Osaki K, Otsuka H, Uomizu K, Harada R, Otsuji Y, Hashimoto S. Monocyte-mediated suppression of mitogen responses of lymphocytes in uremic patients. Nephron 1983; 34: 87–92
   PubMedGoogle Scholar
• Langhoff E, Ladefoged J, Olgaard K, Madoen S. Restoration of uraemic lymphocyte responses in vitro by interleukin-2. Proc EDTA-ERA 1985; 22: 932–936
   Google Scholar
• Gonzalez M, De M, Francisco A L, Canga E, Morales P, Ruiz L, Zubimendi A, Arias M. Effect of C.A.PD. and hemodialysis on the transport of inhibitory factors of lymphocyte proliferation present in uremic serum. Ambulatory Peritoneal Dialysis. Proceedings of the Fourth Congress of the Int. Society for Peritoneal Dialysis, MM Avram, C Giordano. Plenum, New York 1990; 91–92
   Google Scholar
• Alexiewicz J A, Gaciong Z, Klinger M, Linker-Israeli M, Pitts T O, Massry SG. Evidence of impaired T cell function in hemodialysis patients: potential role for secondary hyperparathyroidism. Am J Nephrol 1990; 10: 495–501
   PubMed Web of Science ®Google Scholar
• Tabata T, Suzuki R, Kikunami K, Matsushita Y, Inoue T, Inoue T, Okamoto T, Miki T, Nishizawa Y, Morii H. The effect of 1α-hydroxyvitamin D3 on cell-mediated immunity in hemodialyzed patients. J Clin Endocrinol Metab 1986; 63: 1218–1221
   PubMedGoogle Scholar
• Tabata T, Shoji T, Kikunami K, Matsushita Y, Inoue T, Tanaka S, Hino M, Miki T, Nishizawa Y, Morii H. In vivo effect of 1α-hydroxyvitamin D3 on interleukin-2 production in hemodialysis patients. Nephron 1988; 50: 295–298
   PubMedGoogle Scholar
• Rigby W FC, Stacu T, Fanger MW. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 1984; 74: 1451–1455
   PubMed Web of Science ®Google Scholar
• Han T, Winnicki MS. Indomethacin-mediated enhancement of lymphocyte response to mitogens. In treated and untreated Hodgkin's disease and non-Hodgkin's lymphoma. NYS J Med June, 1980; 1070–1075
   Google Scholar
• Goodwin J S, Bankhurst A D, Messner RP. Suppression of human T-cell mitogenesis by prostaglandin. J Exp Med 1977; 146: 1719–1734
   PubMed Web of Science ®Google Scholar
• Modai D, Weissgarten J, Shaked U, Segal S, Pik A, Fuchs R. Levamisol circumvents inhibition of lymphocyte activation imposed by uremic serum. Nephron 1985; 40: 436–439
   PubMedGoogle Scholar
• Modai D, Weissgarten J, Cohen N, Averbukh Z, Golik A, Peller S, Tieder M, Shaked U, Kaufman S. The effects of uremic serum and 3′-5′ cyclic AMP on blastogenesis of normal lymphocytes. Thymus 1986; 8(5)307–3ll
   PubMedGoogle Scholar
• Goodwin J S, Messner R P, Bankhurst AD. Prostaglandin-producing suppressor cells in Hodgkin's disease. N Engl J Med 1977; 297: 963–968
   PubMed Web of Science ®Google Scholar
• Alevy Y G, Slavin RG. Immune response in experimentally induced uremia. II. Suppression of PHA response in uremia is mediated by an adherent, 1a-negative and indomethacin-insensitive suppressor cell. J Immunol 1981; 126: 2007–2010
   PubMedGoogle Scholar
• Ladefoged J, Langhoff E. Accessory cell functions in mononuclear cell cultures from uremic patients. Kidney Int 1990; 37: 126–130
   PubMedGoogle Scholar
• Raskova J, Ghobrial I, Shea S M, Ebert E C, Eisinger R P, Raska K. T cells in patients undergoing chronic hemodialysis: mitogenic response, suppressor activity and interleukin-2 production and receptor generation. Diagnostic Immunol 1986; 4: 209–216
   PubMedGoogle Scholar
• Kimmel P L, Phillips T M, Phillips E, Bosch JP. Effect of renal replacement therapy on cellular cytokine production in patients with renal disease. Kidney Int 1990; 38: 129–135
   PubMed Web of Science ®Google Scholar
• Lopez-Botet M, Fontan G, Garcia M C, Ortiz De Landazuri M. Relationship between IL-2 synthesis and the proliferative response to PHA in different primary immunodeficiences. J Immunol 1982; 128: 679–683
   PubMedGoogle Scholar
• Greene W C, Leonard W J, Depper J M, Nelson DL, Waldmann TA. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Ann Intern Med 1986; 105: 560–572
   PubMed Web of Science ®Google Scholar
• Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol 1981; 126: 1393–1397
   PubMed Web of Science ®Google Scholar
• Beaurain G, Naret C, Marcon L, Grateau G, Drueke T, Urena P, Nelson D L, Bach J F, Chatenaud L. In vivo T cell preactivation in chronic uremic hemodialyzed and nonhemodialyzed patients. Kidney Int 1989; 36: 636–644
   PubMed Web of Science ®Google Scholar